Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Building on the drugmaker’s HIV grants, this new funding is part of Gilead’s Racial Equity Community Impact Fund.
The U.S. government and HIV drugmaker Gilead Sciences continue to fight over patents for Truvada and Descovy as PrEP.
“All insurers failing to offer PrEP without cost sharing beginning in January 2021 are clearly not following the law.”
Until now, researchers believed that the replication capsid’s main function was to hold viral genetic material.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
Virtually, of course. So take a look around.
4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.
Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.
Nine key findings from a survey of HIV-positive people 50 and older. Plus: A special report on aging with HIV during COVID-19.
NMAC is giving away 100 Apple iPads and Verizon internet hotspots with three months of internet access. Help us identify people in need!
A low-cost generic version of Truvada as PrEP will hit the market September 30.
The results of GLAAD’s first State of HIV Stigma Study coincide with news of a $9 million Gilead grant to fight HIV in the South.
Plus: The Elizabeth Taylor AIDS Foundation and Gilead Sciences join the collective for a virtual town hall June 25.
Safeway and other Albertsons pharmacies will also participate, allowing uninsured clients to fill PrEP prescriptions at no cost.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
Hint: Gilead Sciences donated the meds for Trump’s HIV prevention program, so that cost isn’t the issue.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.